What Is Zomedica Target Price?

Does Zomedica have a future?

Zomedica Corp (NYSE American:ZOM) The 1 analysts offering 12-month price forecasts for Zomedica Corp have a median target of 1.20, with a high estimate of 1.20 and a low estimate of 1.20 The median estimate represents a +377.33% increase from the last price of 0.25.

Is ZOM stock a good buy?

ZOM stock could provide some good gains in the long term if its veterinary diagnostic and therapeutic technologies can gain sufficient market traction. However, the stock remains a speculative investment that owed its previous tops to the Reddit meme that lifted other stocks like GameStop and AMC.

Should I sell my Zomedica stock?

Considering the 90-day investment horizon and your highly speculative risk level, our recommendation regarding Zomedica Pharmaceuticals Corp is ‘ Strong Sell ‘.

Will Zomedica recover?

ZOM stock will likely struggle to recover in price over the next few months It’s going to be awhile before this early stage company will again have the chance to prove itself to investors. Having said that, investors with a high appetite for risk, and a willingness to go against the grain, may want to buy today.

Is Zomedica being shorted?

What is Zomedica’s current short interest? Short interest is the volume of Zomedica shares that have been sold short but have not yet been covered or closed out. As of June 15th, traders have sold 101,490,000 shares of ZOM short. 10.52% of Zomedica’s shares are currently sold short.

Does Zomedica have potential?

This diagnostics tool looks to disrupt a global veterinary diagnostic services market that is large and growing. Estimates are that this market will grow from an estimated valuation of $2.5 billion in 2021 to a projected value of $3.9 billion in 2026 That’s some decent growth.

Is Zomedica a real company?

About us. Zomedica (NYSE American:ZOM) is a veterinary health company focused on meeting the needs of clinical veterinarians in ways that promote both patient and practice health.

Why did Zomedica stock go up?

Shares of Zomedica (ZOM -0.25%) were soaring 14.7% higher as of 11:41 a.m. ET on Monday. The big jump came after the veterinary health company provided a sneak peek at its 2021 fourth-quarter and full-year revenue following the market close on Friday.

Will Zomedica be delisted?

(NYSE American: ZOM) (TSX-V: ZOM) (“Zomedica” or the “Company”) a veterinary diagnostic and pharmaceutical company, today announced that it has received approval of its application to delist its common shares from the TSX Venture Exchange (“TSXV”) effective at the close of business on February 10, 2020.

Why is Zomedica down?

Key Points. Zomedica’s shares have plunged more than 80% after skyrocketing earlier this year. The company has experienced problems with a distribution partner being acquired and a development partner’s delays.

What does Zomedica Corp do?

Zomedica Corp. operates as a veterinary health company, which engages in the discovery, development, and commercialization of pharmaceuticals for the companion pet It offers products for dogs and cats by focusing on the unmet needs of clinical veterinarians.



You May Also Like